Differential Expression of Interneuron Populations and Correlation with Amyloid-β Deposition in the Olfactory Cortex of an AβPP/PS1 Transgenic Mouse Model of Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Impaired olfaction is an early symptom of Alzheimer's disease (AD). Neuroanatomical changes underlying this deficit in the olfactory system are largely unknown. Cell neurodegeneration is known to involve, among others, somatostatin (SST)- and calcium-binding protein-positive cells. We report here quantitative analysis of temporal changes in the distribution of interneuron cell populations in the olfactory cortex of an AβPP/PS1 double-transgenic mouse model of AD and its correlation with amyloid-β pathology. To investigate early stages of pathology, the piriform and lateral entorhinal cortices were analyzed in groups of homozygous AβPP/PS1 and control animals at 2, 4, 6, and 8 months of age. There was a significant increase in brain levels of aggregated amyloid-β peptide with age, accompanied by an early and marked fall in numbers of SST- and calretinin-positive interneurons; a later and less pronounced decrease in levels of calbindin- and parvalbumin-positive cells was also observed. In addition, double-labeling experiments indicated high levels of co-localization of SST-positive cells with amyloid-β expression in olfactory areas. These observations argue that SST-positive cells are vulnerable to amyloid-β neuropathy in the olfactory cortex during the early stages of AD. These data may cast light on the neural basis of hyposmia associated with this disorder and on the mechanisms of cell vulnerability to neurodegeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Gene regulation and DNA damage in the ageing human brain
Lu, T., Pan, Y., Kao, S.-Y., Li, C., Kohane, I., Chan, J., & Yankner, B. A. (2004) · Nature · doi:10.1038/nature02661 · Cited by 1,874
Jankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., Copeland, N. G., Lee, M. K., Younkin, L. H., Wagner, S. L., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh019 · Cited by 1,575 · cited 1×
“mouse prion protein promoter elements [36].”
Citron, M., Westaway, D., Xia, W., Carlson, G., Diehl, T., Levesque, G., Johnson-wood, K., Lee, M., Seubert, P., Davis, A., et al. (1997) · Nature Medicine · doi:10.1038/nm0197-67 · Cited by 1,271 · cited 1×
“FADlinked mutant forms of A PP and PS1 are thought to increase A levels [60] and to enhance the vulnerability of neurons [49]; it was therefore anticipated that the use of homozygous animals would lead to early pathology, thereby permitting the study of interneuron populations and A accumulation very early in the deve…”
BackgroundDavies, P., Katzman, R., & Terry, R. D. (1980) · Nature · doi:10.1038/288279a0 · Cited by 882
Price, J. L., Davis, P. B., Morris, J. C., & White, D. L. (1991) · Neurobiology of Aging · doi:10.1016/0197-4580(91)90006-6 · Cited by 818
Mattson, M. P. (2007) · Aging Cell · doi:10.1111/j.1474-9726.2007.00275.x · Cited by 751 · cited 1×
“Specificmuta-tionsinthegeneencodingpresenilin1( PSEN1 ), a known predisposing factor in some cases of familial (FAD), are thought to increase A levels, and it has of cell pores that induce programmed cell death by altering intracellular calcium levels [29, 30].”
Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease
Garcia-Alloza, M., Robbins, E. M., Zhang-Nunes, S. X., Purcell, S. M., Betensky, R. A., Raju, S., Prada, C., Greenberg, S. M., Bacskai, B. J., & Frosch, M. P. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.08.017 · Cited by 744 · cited 1×
“A PPswe/PSEN1dE9 mouse model (referred to here as A PP/PS1) is characterized by increasing A levels with age [37].”
BackgroundTarget-cell-specific facilitation and depression in neocortical circuits
Reyes, A., Lujan, R., Rozov, A., Burnashev, N., Somogyi, P., & Sakmann, B. (1998) · Nature Neuroscience · doi:10.1038/1092 · Cited by 716 · cited 1×
“SST-positive cortical cells are predominantly GABAergic interneurons [23] and the majority synapse with pyramidal neurons [55].”
BackgroundMultimodal techniques for diagnosis and prognosis of Alzheimer's disease
Perrin, R. J., Fagan, A. M., & Holtzman, D. M. (2009) · Nature · doi:10.1038/nature08538 · Cited by 702 · cited 1×
“Clinically the disease is characterized by progressive loss of memory, motor and cognitive functions [2].”
BackgroundDeFelipe, J. (1997) · Journal of Chemical Neuroanatomy · doi:10.1016/s0891-0618(97)10013-8 · Cited by 550
Palop, J. J., Jones, B., Kekonius, L., Chin, J., Yu, G.-Q., Raber, J., Masliah, E., & Mucke, L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1133381100 · Cited by 402
Kawaguchi, Y., & Kondo, S. (2002) · Journal of Neurocytology · doi:10.1023/a:1024126110356 · Cited by 395 · cited 1×
“First, these cells are predominantly inhibitory -aminobutyric acid (GABA)-ergic neurons; second, their neuronal connectivity is predominantly restricted to local areas of the brain [14].”
BackgroundOn counting and counting errors
Guillery, R. W. (2002) · Journal of Comparative Neurology · doi:10.1002/cne.10221 · Cited by 343
Gender differences in the amount and deposition of amyloidβ in APPswe and PS1 double transgenic mice
Wang, J., Tanila, H., Puoliväli, J., Kadish, I., & Groen, T. V. (2003) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.08.009 · Cited by 316
Buxbaum, J. D., Thinakaran, G., Koliatsos, V., O’Callahan, J., Slunt, H. H., Price, D. L., & Sisodia, S. S. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-23-09629.1998 · Cited by 293
Changing perspectives regarding late-life dementia
Fotuhi, M., Hachinski, V., & Whitehouse, P. J. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.175 · Cited by 291
Olfactory Dysfunction Correlates with Amyloid-β Burden in an Alzheimer's Disease Mouse Model
Wesson, D. W., Levy, E., Nixon, R. A., & Wilson, D. A. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4622-09.2010 · Cited by 290 · cited 1×
“Previous studies with mouse AD models showed that impaired odor habituation and reduced odor discrimination correlated with the spatiotemporal deposition of A [41, 42].”
BackgroundSomatostatin immunoreactivity in neuritic plaques of Alzheimer's patients
Morrison, J. H., Rogers, J., Scherr, S., Benoit, R., & Bloom, F. E. (1985) · Nature · doi:10.1038/314090a0 · Cited by 264 · cited 1×
“Early neuropathology of SST- and CR-positive cells in the hippocampus [51, 52] and entorhinal cortex [53] of similar mouse models and co-localization of SST with A peptide have been described previously [54].”
BackgroundSeverely dystrophic axons at amyloid plaques remain continuous and connected to viable cell bodies
Adalbert, R., Nogradi, A., Babetto, E., Janeckova, L., Walker, S. A., Kerschensteiner, M., Misgeld, T., & Coleman, M. P. (2009) · Brain · doi:10.1093/brain/awn312 · Cited by 177
Parvalbumin-immunoreactive neurons in the hippocampal formation of Alzheimer’s diseased brain
Brady, D. R., & Mufson, E. J. (1997) · Neuroscience · doi:10.1016/s0306-4522(97)00068-7 · Cited by 125 · cited 1×
“Although some researchers have suggested that CaBP-positive cells are particularly vulnerable to neurodegenerative processes in AD, others have postulated instead that altered CaBP expression reflects compensatory changes taking place in the brain and that CaBPs contribute to protection against neurodegeneration [32–3…”
BackgroundHippocampal interneuron loss in an APP/PS1 double mutant mouse and in Alzheimer’s disease
Takahashi, H., Brasnjevic, I., Rutten, B. P. F., Van Der Kolk, N., Perl, D. P., Bouras, C., Steinbusch, H. W. M., Schmitz, C., Hof, P. R., & Dickstein, D. L. (2010) · Brain Structure and Function · doi:10.1007/s00429-010-0242-4 · Cited by 124 · cited 1×
“However, some reports have described no changes in PV- and CR-immunoreactive neurons in the frontal cortex of a double-transgenic mouse model [43], whereas others have described a profound reduction of CaBP-positive cell expression in areas such as the hippocampus [44], and these were comparable to the reductions seen…”
ResultSheng, J. G., Price, D. L., & Koliatsos, V. E. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-22-09794.2002 · Cited by 124 · cited 1×
“A deposition has been related to A PP transport and processing through cortico-cortical pathways [62], and disruption of cortico-cortical connections has been reported to lead to reduced A levels [63].”
BackgroundBaglietto-Vargas, D., Moreno-Gonzalez, I., Sanchez-Varo, R., Jimenez, S., Trujillo-Estrada, L., Sanchez-Mejias, E., Torres, M., Romero-Acebal, M., Ruano, D., Vizuete, M., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100066 · Cited by 98
Popović, M., Caballero-Bleda, M., Kadish, I., & Van Groen, T. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.05.023 · Cited by 38 · cited 1×
“However, some reports have described no changes in PV- and CR-immunoreactive neurons in the frontal cortex of a double-transgenic mouse model [43], whereas others have described a profound reduction of CaBP-positive cell expression in areas such as the hippocampus [44], and these were comparable to the reductions seen…”
ResultLemmens, M. A. M., Sierksma, A. S. R., Rutten, B. P. F., Dennissen, F., Steinbusch, H. W. M., Lucassen, P. J., & Schmitz, C. (2011) · Brain Structure and Function · doi:10.1007/s00429-011-0305-1 · Cited by 37
Cited by
GABAergic Inhibitory Interneuron Deficits in Alzheimer’s Disease: Implications for Treatment
Xu, Y., Zhao, M., Han, Y., & Zhang, H. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00660 · Cited by 203
Amyloid-β Deposition and Olfactory Dysfunction in an Alzheimer's Disease Model
Wu, N., Rao, X., Gao, Y., Wang, J., & Xu, F. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-122443 · Cited by 89
Interneurons, tau and amyloid-β in the piriform cortex in Alzheimer’s disease
Saiz-Sanchez, D., De la Rosa-Prieto, C., Ubeda-Banon, I., & Martinez-Marcos, A. (2015) · Brain Structure and Function · doi:10.1007/s00429-014-0771-3 · Cited by 79
Albuquerque, M. S., Mahar, I., Davoli, M. A., Chabot, J.-G., Mechawar, N., Quirion, R., & Krantic, S. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00030 · Cited by 71
“…neurons occurs later and is less pronounced in the course of AD-like pathology than the loss of other types of GABAergic neurons (e.g., SOMor calretinin-expressing neurons) in both olfactory bulb (SaizSanchez et al., 2013) and olfactory cortex (Saiz-Sanchez et al., 2012) of the APPxPS1 mice.”
BackgroundZallo, F., Gardenal, E., Verkhratsky, A., & Rodríguez, J. J. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.05.027 · Cited by 57
Metadata
- Authors
- Saiz-Sanchez, D., Ubeda-Bañon, I., De la Rosa-Prieto, C., & Martinez-Marcos, A.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2012-07-05
- Volume
- 31
- Issue
- 1
- Pages
- 113-129
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1510052211
- Cited by
- 45
- References
- 26
- FWCI
- 1.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.